{"DataElement":{"publicId":"4890174","version":"1","preferredName":"Patient Receive Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial with regards to administration of therapy.","longName":"PT_RCVD_TX_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"4890173","version":"1","preferredName":"Patient Receive Therapeutic Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._To take, accept, or get something offered._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:4890171v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4890171","version":"1","preferredName":"Receive Therapeutic Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"To take, accept, or get something offered.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C25639:C49236:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19D177A1-81E8-0A2C-E050-BB89AD434D64","latestVersionIndicator":"Yes","beginDate":"2015-07-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-07-01","modifiedBy":"ONEDATA","dateModified":"2015-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"19D177A1-81F9-0A2C-E050-BB89AD434D64","latestVersionIndicator":"Yes","beginDate":"2015-07-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-07-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000494","version":"1","longName":"Prior Treatments","context":"Theradex"}]},{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient received prior therapy with mTOR inhibitors except for rapalog treatment as part of GVH prophylaxis or treatment?","url":null,"context":"Theradex"},{"name":"Has patient received more tha","type":"Preferred Question Text","description":"Has patient received more than 2 lines of therapy beyond corticosteroids with or without calcineurin inhibitors or sirolimus?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Has patient received Trastuzumab, Bevacizumab, or nitrosoureas/mitomycin C less than 6 weeks prior to registration?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has patient not received prior therapy with mTOR inhibitors except for rapalog treatment as part of GVH prophylaxis or treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Has patient received no more than 1 prior regimen in the platinum resistant setting?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Is patient receiving adjuvant chemoradiation after surgical resection of the primary site of disease?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Has patient received ibrutinib within 2 weeks prior to beginning therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient has ovarian cancer and a BRCA mutation, has patient received prior treatment with olaparib per guidelines for standard care treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Has patient received at least two prior chemotherapeutic or biologic (e.g., Rituximab alone) regimens and is not currently eligible for standard curative options?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Has patient received neoadjuvant or adjuvant therapy within 6 months prior to diagnosis of metastatic disease?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Has patient had less than or equal to 3 lines of prior therapy in the metastatic disease setting?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Patient has not received prior P13K, AKT or mTor inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Has patient received at least two prior lines of therapy for mCRPC?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Has patient received prior P13K, AKT,or mTOR inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Was last dose of prior cytotoxic chemotherapy received at least 28 days prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Has patient received one prior systemic chemotherapeutic regimen for management of recurrent, persistent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab)?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Has patient received prior ACT infusion within 6 months of study enrollment (cohorts include ACT with TIL, HLA-class I TCR-engineered lymphocytes, HLA-class II TCR-engineered lymphocytes, and CAR-engineered T cells)?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Has patient received greater than 2 prior chemotherapy regimens for the current malignancy (full dose chemotherapy in conjunction with concurrent radiation therapy will be included in prior therapy)?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Has patient received one prior systemic chemotherapeutic regimen for management of recurrent, persistent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/Bevacizumab) at least one of which must have contained bevacizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Is patient currently receiving medications or herbal supplements noted below which cannot be discontinued at least 1 week prior to receiving any protocol treatment or as specified in protocol section 5.3?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Has patient received at least one prior line of therapy for mCRPC?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Has patient received at least one line of standard systemic treatment for locally advanced or metastatic disease setting of the respective tumor type?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Has patient received at least one line of platinum-based chemotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Has patient received prior platinum based chemotherapy?","url":null,"context":"Theradex"},{"name":"Thradex - 27","type":"Alternate Question Text","description":"Has patient received treatment with cytotoxic chemotherapy, hormonal therapies (including but not limited to abiraterone, enzalutamide), or investigational prostate cancer directed therapy within 4 weeks of treatment initiation?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Has patient received less than or equal to 2 prior platinum regimens?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Has patient received at least 2 prior treatments for castration resistant prostate cancer as follows: past progression or intolerance to at least one secondary hormonal therapy (abiraterone, enzalutamide, galeterone, apalutamide, darolutamide, orteronel, seviteronel or equivalent); past progression or intolerance to taxane-based chemotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"If prostate cancer patient is registered to the disease specific expansion cohort, does patient have metastatic or advanced (incurable and unresectable) castration resistant metastatic cancer and has patient received at least one additional line of anti-androgen therapy with abiraterone or enzalutamide?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Has patient received prior ACT infusion within 9 months of study enrollment (cohorts include ACT with TIL, HLA-class I TCR-engineered lymphocytes, HLA-class II TCR-engineered lymphocytes, and CAR-engineered T cells)?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"If patient has received taxane-based adjuvant therapy, have they had a disease-free interval of at least 12 months after completion of taxane therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Has patient received at least one or more prior lines of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"If prostate cancer patient is registered to the disease specific expansion cohort (applies to all prostate cancer patients in parts 1, 2, and 3), does patient have metastatic or advanced (incurable and unresectable) castration resistant metastatic cancer and has patient received at least one additional line of anti-androgen therapy with abiraterone or enzalutamide?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Has patient received at least two prior lines of therapy and have been exposed to a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD-38 antibody?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"If patient has received chemotherapy in the past 6 months and CD4 count was less than 250 cells/mcL during chemotherapy was viral load undetectable during this same chemotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Has patient been previously treated with MLN9708 or venetoclax or other direct BCL2 inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Has patient received at least two prior lines of therapy?","url":null,"context":"Theradex"},{"name":"NRG_CRF_Text1","type":"Alternate Question Text","description":"Did the patient receive at least 2 cycles of pemetrexed/platinum chemotherapy and undergo a pleurectomy/decortication following step 1 registration?","url":null,"context":"NRG"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Has patient received one to three lines of therapy for their disease with a line of therapy defined as one or more cycles of a planned treatment program?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Is patient medically eligible to receive MEC, including acceptable pre-study cardiac function (left ventricular ejection fraction of greater than or equal to 45%) and lifetime anthracycline exposure (less than or equal to 360 mg/m2 daunorubicin equivalents)?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Has patient received treatment with abiraterone, apalutamide or darolutamide within 2 weeks of treatment initiation?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"If patient is enrolled in Phase 2 portion of the study and has MSI-H or NTRK-fusion positive tumors, has patient received approved treatment for these tumor types?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Is patient eligible to receive therapy with paclitaxel for the treatment of their breast cancer?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Has patient received a known CYP2C8 substrate with a narrow therapeutic window within 14 days prior to receiving first dose of KRT-232 (AMG 232) or will receive such medications during the study?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Has patient received chemotherapy (including antibody drug therapy, retinoid therapy, hormonal therapy for cancer),  small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, weekly paclitaxel within 4 weeks prior to enrollment or five half-lives, whichever is shorter or within 6 weeks for nitrosoureas or mitomycin C?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Does patient fit into one of the categories: is receiving active treatment (defined as current treatment or treatment within the past 6 weeks) for metastatic cancer. is receiving adjuvant treatment for non-metastatic (Stage I-III) cancer and has received intravenous chemotherapy, immunotherapy, targeted therapy, or radiation therapy within the past 6 weeks; or has received an allogenic stem cell transplant or CAR-T cell or other modified cellular therapy at any time; or is currently receiving treatment or prophylaxis for Graft vs. Host Disease; or has received an autologous bone marrow transplant within the past 2 years?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Has patient used any known CYP2C8 substrates with a narrow therapeutic window within the 14 days prior to receiving the first dose of KRT-232 (AMG 232)?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Has patient received treatment for this disease?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Is patient taking bisphosphonate therapy for symptomatic hypercalcemia?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are inhibitors or inducers of triapine, as well as medications known to be associated with methemoglobinemia?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Is patient receiving active cancer treatment in one of the eligible categories?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Has patient received ACT infusion prior to study enrollment (cohorts include ACT with TIL, HLA-class I TCR-engineered lymphocytes, HLA-class II TCR-engineered lymphocytes, and CAR-engineered T cells)?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Is patient with prostate cancer continuing to receive treatment with GnRH agonists while on study, without evidence of disease progression on prior therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Patient has not received myelosuppressive chemotherapy within 3 weeks of leukapheresis (6 weeks if prior nitrosourea)?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Has patient received any therapy for MDS, CMML, or MPN (conventional or unconventional) within 2 weeks prior to treatment with CPX-351?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Has patient received myelosuppressive chemotherapy within 3 weeks of leukapheresis (6 weeks if prior nitrosourea)?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"Is patient taking any medication associated with methemoglobinemia?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"If patient is enrolled to the atezolizumab + bevacizumab combination arm, is patient receiving chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID), clopidogrel, dypiridamole, or aspirin therapy more than 81 mg/day?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"Has patient received prior treatment with CD47 or SIRPa-targeting agents?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"If patient is in the expansion cohorts, has patient received less than or equal to 2 prior lines in the platinum-resistant setting?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"Is patient a candidate to receive EP?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"Is patient receiving prophylactic/suppressive antibiotics?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Does patient have concurrent use of calcineurin-inhibitor plus sirolimus?","url":null,"context":"COG"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"Has patient received a minimum of one standard regimen exposure in a metastatic setting?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Does patient regularly use (not occasional) analgesic medication for cancer-related bone pain or have undergone treatment with EBRT for bone pain within 4 weeks before starting study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"Is the patient likely to begin treatment, scheduled to begin treatment, OR currently being treated with an Appendix A therapy?","url":null,"context":"Theradex"},{"name":"NRG_CRF_Text3","type":"Alternate Question Text","description":"Did the patient receive at least 2 cycles of prior neoadjuvant systemic therapy?","url":null,"context":"NRG"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"Has patient received treatment with any other agent administered for the treatment of the patient's cancer, within five half-lives or 4 weeks prior to Cycle 1, Day 1, whichever is shorter?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"Is patient receiving H2 blockers and proton pump inhibitors?","url":null,"context":"Theradex"},{"name":"NRG_CRF_Text2","type":"Alternate Question Text","description":"Did the patient receive at least 2 cycles of systemic therapy and undergo a pleurectomy/decortication?","url":null,"context":"NRG"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"Has patient received anti-plasma cell therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"If patient is receiving hydroxyurea to control counts, is WBC less than 10,000/mm3 as determined more than 24 hours after the last dose of hydroxyurea?","url":null,"context":"Theradex"},{"name":"Alliance Text - 1","type":"Alternate Question Text","description":"Prior cancer-directed therapy?","url":null,"context":"Alliance"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Has patient had calcineurin inhibitors within the last 28 days or is receiving a physiologic dose of steroids greater than the indicated range?","url":null,"context":"COG"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"Will patient exceed a lifetime anthracycline exposure of greater than 550 mg/m2 daunorubicin or equivalent (or greater than 400 mg/m2 daunorubicin or equivalent in the event of prior mediastinal radiation) if they receive the maximum potential exposure to anthracyclines per protocol (including both induction and reinduction cycles)?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"Has patient received chemotherapy (including antibody drug therapy, retinoid therapy, hormonal therapy for cancer), with the exception of standard of care androgen deprivation treatment, as noted in section 3.1.11) small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, weekly paclitaxel within 4 weeks prior to enrollment or five half-lives, whichever is shorter  or within 6 weeks for nitrosoureas or mitomycin C?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"19D177A1-8211-0A2C-E050-BB89AD434D64","latestVersionIndicator":"Yes","beginDate":"2015-07-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-07-01","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeDescription":"7/12/18 tt changed reg status from 'qualified' to 'application'/BR. 12/6/16 tt - added CSI. 9/10/15 added CSI.tt","administrativeNotes":"1/19/2023: added AQT per CADSR0001933.wz","unresolvedIssues":null,"deletedIndicator":"No"}}